Invizyne Technologies Inc. Common Stock
Invizyne Technologies, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The c… Read more
Invizyne Technologies Inc. Common Stock (IZTC) - Net Assets
Latest net assets as of December 2024: $10.42 Million USD
Based on the latest financial reports, Invizyne Technologies Inc. Common Stock (IZTC) has net assets worth $10.42 Million USD as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($13.03 Million) and total liabilities ($2.61 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $10.42 Million |
| % of Total Assets | 79.95% |
| Annual Growth Rate | 105.68% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 71.33 |
Invizyne Technologies Inc. Common Stock - Net Assets Trend (2021–2024)
This chart illustrates how Invizyne Technologies Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Invizyne Technologies Inc. Common Stock (2021–2024)
The table below shows the annual net assets of Invizyne Technologies Inc. Common Stock from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $10.42 Million | +2811.49% |
| 2023-12-31 | $-384.32K | -128.00% |
| 2022-12-31 | $1.37 Million | +14.66% |
| 2021-12-31 | $1.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Invizyne Technologies Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 929585200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $22.37 Million | 214.64% |
| Total Equity | $10.42 Million | 100.00% |
Invizyne Technologies Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Invizyne Technologies Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pattern Group Inc. Series A Common Stock
NASDAQ:PTRN
|
$106.11K |
|
HEIWA REAL ESTATE - Dusseldorf Stock Exchang
DU:HZJ
|
$106.14K |
|
PIMCO DYN.INC.OP.BEN.
F:V37
|
$106.15K |
|
SVENSKA CELLULO -B- - Dusseldorf Stock Exchang
DU:SCA
|
$106.18K |
|
FOMENTO CONSTR. - Dusseldorf Stock Exchang
DU:FCC
|
$106.03K |
|
Fresh Harvest Products Inc
PINK:IMTH
|
$105.98K |
|
Portman Ridge Finance Corp
NASDAQ:PTMN
|
$105.93K |
|
South Ocean Holdings Ltd
JSE:SOH
|
$105.87K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Invizyne Technologies Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -384,319 to 10,420,775, a change of 10,805,094.
- Net loss of 5,861,335 reduced equity.
- New share issuances of 14,528,964 increased equity.
- Other factors increased equity by 2,137,465.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.86 Million | -56.25% |
| Share Issuances | $14.53 Million | +139.42% |
| Other Changes | $2.14 Million | +20.51% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Invizyne Technologies Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.44x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 79.77x to 9.44x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $0.15 | $11.75 | x |
| 2022-12-31 | $0.17 | $11.75 | x |
| 2023-12-31 | $-0.05 | $11.75 | x |
| 2024-12-31 | $1.25 | $11.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Invizyne Technologies Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -56.25%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.25x
- Recent ROE (-56.25%) is above the historical average (-64.74%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -101.00% | 0.00% | 0.00x | 1.96x | $-1.33 Million |
| 2022 | -101.72% | 0.00% | 0.00x | 1.96x | $-1.53 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.00 Million |
| 2024 | -56.25% | 0.00% | 0.00x | 1.25x | $-6.90 Million |
Industry Comparison
This section compares Invizyne Technologies Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Invizyne Technologies Inc. Common Stock (IZTC) | $10.42 Million | -101.00% | 0.25x | $106.10K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |